Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7336 to 7350 of 7708 results

  1. Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

    Discontinued [GID-TA10750]

    Technology appraisal guidance
    Discontinued

  2. Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]

    In development [GID-TA10758] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

    In development [GID-TA10933] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

    In development [GID-TA11009] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Surgical correction of hallux valgus using minimal access techniques (IPG332)

    This guidance has been updated and replaced by NICE interventional procedures guidance 789. 

    Interventional procedures guidance
    Published
    24 February 2010

  6. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    In development [GID-TA11166] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    In development [GID-TA11089] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

    In development [GID-TA11411] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

    Technology appraisal guidance
    Published
    27 July 2016

  10. Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]

    In development [GID-TA11580] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development [GID-TA10745] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  12. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007

    In development [GID-TA11567] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920

    In development [GID-TA11482] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]

    In development [GID-TA11475] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development [GID-TA11301] Expected publication date: TBC

    Technology appraisal guidance
    In development